易方达全球医药行业混合发起式(QDII)A(人民币)(008284)利润分配表
| |
2024-12-31 |
2024-06-30 |
2023-12-31 |
2023-06-30 |
| 收入 |
-146,432,450.81 |
-182,698,138.67 |
-215,616,698.11 |
-239,330,986.76 |
| 利息合计 |
265,901.57 |
93,571.20 |
326,269.51 |
170,786.92 |
| 其中：存款利息收入 |
265,901.57 |
93,571.20 |
326,269.51 |
170,786.92 |
| 债券利息收入 |
- |
- |
- |
- |
| 资产支持证券利息收入 |
- |
- |
- |
- |
| 买入返售金融资产收入 |
- |
- |
- |
- |
| 投资收益合计 |
-411,392,997.88 |
-166,914,599.99 |
-84,031,692.98 |
-49,060,477.13 |
| 其中：股票投资收益 |
-415,457,338.68 |
-168,322,529.38 |
-86,935,499.57 |
-51,660,200.79 |
| 基金投资收益 |
- |
- |
- |
- |
| 债券投资收益 |
666,007.55 |
331,882.87 |
157,643.35 |
4,446.50 |
| 资产支持证券投资收益 |
- |
- |
- |
- |
| 衍生工具收益 |
- |
- |
- |
- |
| 股利收益 |
3,398,333.25 |
1,076,046.52 |
2,746,163.24 |
2,595,277.16 |
| 基金分红收益收益 |
- |
- |
- |
- |
| 公允价值变动收益 |
264,226,015.11 |
-16,149,533.07 |
-132,076,467.80 |
-191,316,088.02 |
| 其他收入 |
526,307.74 |
219,798.16 |
1,556,217.63 |
1,177,981.08 |
| 费用 |
14,781,960.24 |
7,015,658.59 |
19,263,696.73 |
10,935,497.10 |
| 管理人报酬 |
12,103,483.61 |
5,819,436.50 |
16,187,419.88 |
9,214,819.50 |
| 基金托管费 |
2,017,247.19 |
969,906.02 |
2,697,903.28 |
1,535,803.24 |
| 销售服务费 |
346,165.74 |
62,765.88 |
914.60 |
- |
| 交易费用 |
- |
- |
- |
- |
| 利息支出 |
- |
- |
- |
- |
| 其中：卖出回购金融资产支出 |
- |
- |
- |
- |
| 其他费用 |
315,019.86 |
163,526.07 |
377,417.97 |
184,858.28 |
| 利润总额 |
-161,214,411.05 |
-189,713,797.26 |
-234,880,394.84 |
-250,266,483.86 |
微信公众号
证券之星APP
基本资料
